Gilead Sciences, Inc. GILD shares are trading higher on Wednesday, after a study of the company's remdesivir by the National Institute of Allergy and Infectious Diseases met its primary endpoint.
Remdesivir is being evaluated as a potential coronavirus treatment candidate.
See Also: Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial
Gilead Sciences is an American biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Gilead shares were trading up 4.22% at $81.99 on Wednesday. The stock has a 52-week high of $85.97 and a 52-week low of $60.89.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
